Saluda Medical, Inc. (ASX:SLD)

Market Cap	61.75M
Revenue (ttm)	130.35M +28.2%
Net Income	-346.36M
EPS	-2.14
Shares Out	252.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250,804
Open	0.2600
Previous Close	0.2450
Day's Range	0.2450 - 0.2600
52-Week Range	0.2450 - 2.6500
Beta	n/a
Analysts	Strong Buy
Price Target	1.66 (+576.33%)
Est. Earnings	Nov 25, 2026

About Saluda Medical

Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally. The company offers a closed-loop, dose-control platform which senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. It provides Evoke, an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 133
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SLD

Financial Performance

In fiscal year 2026, Saluda Medical's revenue was $90.18 million, an increase of 28.17% compared to the previous year's $70.36 million. Losses were -$239.61 million, 60.5% more than in 2025.

Financial numbers in USD

Analyst Summary

According to 3 analysts, the average rating for SLD stock is "Strong Buy." The 12-month stock price target is $1.66, which is an increase of 576.33% from the latest price.

Price Target

$1.66

(576.33% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 2, 2026

Data Sources Report a data error